518 related articles for article (PubMed ID: 25196265)
1. Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.
Müller T
Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1423-32. PubMed ID: 25196265
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
3. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
5. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
[TBL] [Abstract][Full Text] [Related]
6. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.
Stocchi F; Rabey JM
Eur J Neurol; 2011 Dec; 18(12):1373-8. PubMed ID: 21895884
[TBL] [Abstract][Full Text] [Related]
7. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
Pagonabarraga J; Rodríguez-Oroz MC
Rev Neurol; 2013 Jan; 56(1):25-34. PubMed ID: 23250679
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
Henchcliffe C; Schumacher HC; Burgut FT
Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
[TBL] [Abstract][Full Text] [Related]
9. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Fernandez HH; Chen JJ
Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
[TBL] [Abstract][Full Text] [Related]
10. Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.
Chen JJ; Fernandez HH
Drugs Aging; 2007; 24(8):663-80. PubMed ID: 17702535
[TBL] [Abstract][Full Text] [Related]
11. Rasagiline: a review of its use in the management of Parkinson's disease.
Oldfield V; Keating GM; Perry CM
Drugs; 2007; 67(12):1725-47. PubMed ID: 17683172
[TBL] [Abstract][Full Text] [Related]
12. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
13. Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline.
Degli Esposti L; Piccinni C; Sangiorgi D; Nobili F; Buda S
Neurol Sci; 2016 Feb; 37(2):227-34. PubMed ID: 26474874
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study.
Cereda E; Cilia R; Canesi M; Tesei S; Mariani CB; Zecchinelli AL; Pezzoli G
J Neurol; 2017 Jun; 264(6):1254-1263. PubMed ID: 28550482
[TBL] [Abstract][Full Text] [Related]
15. Rasagiline in Parkinson's disease: the show must go on.
Jost WH
Expert Opin Drug Saf; 2013 Nov; 12(6):797-800. PubMed ID: 23909684
[No Abstract] [Full Text] [Related]
16. Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus.
Hamaue N; Ogata A; Terado M; Tsuchida S; Yabe I; Sasaki H; Hirafuji M; Togashi H; Aoki T
Brain Res; 2010 Jan; 1309():110-5. PubMed ID: 19879254
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease.
Marconi S; Zwingers T
Eur Rev Med Pharmacol Sci; 2014 Jul; 18(13):1879-82. PubMed ID: 25010617
[TBL] [Abstract][Full Text] [Related]
18. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
Parkinson Study Group
Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
[TBL] [Abstract][Full Text] [Related]
19. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
Fernandez HH; Chen JJ
Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
[TBL] [Abstract][Full Text] [Related]
20. A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease.
Jost WH
J Neural Transm (Vienna); 2022 Jun; 129(5-6):723-736. PubMed ID: 35107654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
